Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MNMD Mind Medicine (MindMed)	$7.05 -0.6%	$6.77	$4.70 ▼ $10.44	$532.65M	2.52	1.35 million shs	1.27 million shs
RAPT Rapt Therapeutics	$7.43 +0.1%	$7.46	$5.67 ▼ $30.60	$122.86M	-0.11	161,891 shs	152,905 shs
SAGE Sage Therapeutics	$9.30 +1.9%	$7.20	$4.62 ▼ $13.47	$582.37M	0.18	1.27 million shs	2.60 million shs
UPB Upstream Bio	$10.88 +2.3%	$9.54	$5.14 ▼ $29.46	$585.28M	N/A	338,281 shs	798,298 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MNMD Mind Medicine (MindMed)	0.00%	-1.67%	-0.28%	+4.91%	-3.69%
RAPT Rapt Therapeutics	0.00%	-10.70%	+8.23%	-29.10%	-70.89%
SAGE Sage Therapeutics	0.00%	+38.81%	+40.70%	+14.81%	-13.49%
UPB Upstream Bio	0.00%	-4.23%	+16.86%	+42.78%	+1,087,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MNMD Mind Medicine (MindMed)	1.4097 of 5 stars	3.6	0.0	0.0	1.4	0.8	0.6
RAPT Rapt Therapeutics	3.9016 of 5 stars	3.2	1.0	4.2	2.6	1.7	1.3
SAGE Sage Therapeutics	2.9444 of 5 stars	2.0	1.0	4.0	2.9	1.7	0.6
UPB Upstream Bio	2.1149 of 5 stars	3.5	0.0	0.0	2.6	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MNMD Mind Medicine (MindMed)	3.27	Buy	$25.50	261.70% Upside
RAPT Rapt Therapeutics	2.33	Hold	$24.00	223.01% Upside
SAGE Sage Therapeutics	2.00	Hold	$8.93	-3.94% Downside
UPB Upstream Bio	3.00	Buy	$56.50	419.30% Upside

Current Analyst Ratings Breakdown

Latest RAPT, MNMD, SAGE, and UPB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	SAGE Sage Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$9.00 ➝ $8.50
6/17/2025	SAGE Sage Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Hold ➝ Hold	$8.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$12.00
6/17/2025	SAGE Sage Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$8.00 ➝ $8.50
6/16/2025	SAGE Sage Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/22/2025	RAPT Rapt Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $8.00
5/22/2025	RAPT Rapt Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$48.00
5/13/2025	MNMD Mind Medicine (MindMed)	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/9/2025	MNMD Mind Medicine (MindMed)	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/25/2025	SAGE Sage Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold

(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	$3.21 per share	N/A
RAPT Rapt Therapeutics	$1.53M	80.32	N/A	N/A	$11.51 per share	0.65
SAGE Sage Therapeutics	$41.24M	14.12	N/A	N/A	$7.60 per share	1.22
UPB Upstream Bio	$2.37M	246.93	N/A	N/A	$8.77 per share	1.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MNMD Mind Medicine (MindMed)	-$108.68M	-$1.29	N/A	N/A	N/A	N/A	-40.33%	-32.13%	8/12/2025 (Estimated)
RAPT Rapt Therapeutics	-$129.87M	-$2.40	N/A	N/A	N/A	N/A	-81.47%	-70.24%	8/6/2025 (Estimated)
SAGE Sage Therapeutics	-$400.67M	-$5.80	N/A	N/A	N/A	-747.63%	-68.99%	-60.67%	7/30/2025 (Estimated)
UPB Upstream Bio	-$62.81M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/5/2025 (Estimated)

Latest RAPT, MNMD, SAGE, and UPB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	MNMD Mind Medicine (MindMed)	-$0.36	-$0.35	+$0.01	-$0.35	N/A	N/A
5/8/2025	Q1 2025	RAPT Rapt Therapeutics	-$2.48	-$0.64	+$1.84	-$0.08	N/A	N/A
5/6/2025	Q1 2025	UPB Upstream Bio	-$0.49	-$0.51	-$0.02	-$0.51	$0.71 million	$0.57 million
4/29/2025	Q1 2025	SAGE Sage Therapeutics	-$0.99	-$1.01	-$0.02	-$1.01	$14.12 million	$14.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	N/A
RAPT Rapt Therapeutics	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	N/A	N/A	N/A	N/A	N/A
UPB Upstream Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MNMD Mind Medicine (MindMed)	0.10	7.27	7.27
RAPT Rapt Therapeutics	N/A	21.11	21.11
SAGE Sage Therapeutics	N/A	9.13	9.13
UPB Upstream Bio	N/A	47.43	47.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MNMD Mind Medicine (MindMed)	27.91%
RAPT Rapt Therapeutics	99.09%
SAGE Sage Therapeutics	99.22%
UPB Upstream Bio	N/A

Insider Ownership

Company	Insider Ownership
MNMD Mind Medicine (MindMed)	2.26%
RAPT Rapt Therapeutics	6.60%
SAGE Sage Therapeutics	5.50%
UPB Upstream Bio	13.56%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MNMD Mind Medicine (MindMed)	40	75.55 million	73.85 million	Optionable
RAPT Rapt Therapeutics	80	16.54 million	15.45 million	Optionable
SAGE Sage Therapeutics	690	62.62 million	59.18 million	Optionable
UPB Upstream Bio	38	53.79 million	46.50 million	N/A

RAPT, MNMD, SAGE, and UPB Headlines

Recent News About These Companies

Upstream Bio (NASDAQ:UPB) Trading 7.8% Higher - Should You Buy?

June 20 at 1:45 PM | marketbeat.com

Upstream Bio (NASDAQ:UPB) Shares Gap Down - What's Next?

June 18, 2025 | marketbeat.com

Upstream Bio (NASDAQ:UPB) Trading Down 3.4% - Here's What Happened

June 16, 2025 | marketbeat.com

Upstream Bio, Inc.’s Verekitug: A Promising Contender in the TSLPR Antibody Space

June 16, 2025 | tipranks.com

Upstream Bio Stock Gets A Boost As New Lung Inflammation Drug Shows Higher Potency

June 16, 2025 | msn.com

Upstream Bio Presents Pharmacology Modeling Data Supporting Verekitug's Potency over Tezepelumab at EAACI Congress

June 15, 2025 | quiverquant.com

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

June 15, 2025 | globenewswire.com

Upstream Bio (NASDAQ:UPB) Raised to Hold at Wall Street Zen

June 7, 2025 | marketbeat.com

Upstream Bio, Inc. to Present TSLP Receptor Targeting Data for Verekitug at EAACI Congress 2025

June 5, 2025 | quiverquant.com

Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025

June 5, 2025 | globenewswire.com

Upstream Bio (NASDAQ:UPB) Trading Down 3.4% - Should You Sell?

June 4, 2025 | marketbeat.com

Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

June 4, 2025 | globenewswire.com

Upstream Bio (NASDAQ:UPB) Trading 10.2% Higher - Here's What Happened

June 3, 2025 | marketbeat.com

1,583,154 Shares in Upstream Bio, Inc. (NASDAQ:UPB) Purchased by Wellington Management Group LLP

June 1, 2025 | marketbeat.com

Jane Street Group LLC Takes Position in Upstream Bio, Inc. (NASDAQ:UPB)

May 27, 2025 | marketbeat.com

Northern Trust Corp Makes New Investment in Upstream Bio, Inc. (NASDAQ:UPB)

May 27, 2025 | marketbeat.com

Woodline Partners LP Buys New Stake in Upstream Bio, Inc. (NASDAQ:UPB)

May 25, 2025 | marketbeat.com

VR Adviser LLC Takes $37.74 Million Position in Upstream Bio, Inc. (NASDAQ:UPB)

May 22, 2025 | marketbeat.com

Upstream Bio names new chief technology officer

May 21, 2025 | investing.com

Upstream Bio Appoints Stacy Price As CTO

May 21, 2025 | nasdaq.com

Upstream Bio, Inc. Appoints Stacy Price as Chief Technology Officer to Lead Expansion of Technical Operations

May 21, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RAPT, MNMD, SAGE, and UPB Company Descriptions

Mind Medicine (MindMed) NASDAQ:MNMD

$7.05 -0.04 (-0.56%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$7.04 -0.01 (-0.14%)

As of 06/20/2025 07:49 PM Eastern

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Rapt Therapeutics NASDAQ:RAPT

$7.43 +0.01 (+0.13%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$7.64 +0.22 (+2.89%)

As of 06/20/2025 04:20 PM Eastern

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

Sage Therapeutics NASDAQ:SAGE

$9.30 +0.17 (+1.86%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$9.17 -0.13 (-1.40%)

As of 06/20/2025 07:57 PM Eastern

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Upstream Bio NASDAQ:UPB

$10.88 +0.24 (+2.26%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$10.91 +0.03 (+0.28%)

As of 06/20/2025 07:21 PM Eastern

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time